Point of Care Molecular Diagnostics Market: By Product and Service (Assays & Kits, Instruments & Analyzers, Software & Services), By Technology (RT-PCR, INAAT, Other Technologies), By Application (Respiratory Diseases, Sexually Transmitted Diseases, Hospital-acquired Infections, Cancer, Hepatitis, Gastrointestinal Disorders, Other Applications), By End-User (Physicians’ Offices, Hospitals & ICUs, Research Institutes, Other End Users) And Region – Global Analysis of Market Size, Share & Trends For 2019–2021 And Forecasts To 2031
Point of Care Molecular Diagnostics Market: By Product and Service (Assays & Kits, Instruments & Analyzers, Software & Services), By Technology (RT-PCR, INAAT, Other Technologies), By Application (Respiratory Diseases, Sexually Transmitted Diseases, Hospital-acquired Infections, Cancer, Hepatitis, Gastrointestinal Disorders, Other Applications), By End-User (Physicians’ Offices, Hospitals & ICUs, Research Institutes, Other End Users) And Region – Global Analysis of Market Size, Share & Trends For 2019–2021 And Forecasts To 2031
PRODUCT OVERVIEW
Molecular diagnostic testing blends laboratory testing with molecular biology precision, revolutionizing how clinical and public health laboratories explore human, viral, and microbial genomes, genes, and the products they encode. Various conventional tests have been replaced by molecular diagnostic assays in many areas of laboratory medicine, including infectious diseases, oncology, clinical genetics, and clinical chemistry. Furthermore, advances in molecular diagnostic testing will continue to improve the precision and speed with which we can detect microbial infections or study a patient's genes, and it will become an increasingly important part of patient-tailored interventions and medicines.
MARKET HIGHLIGHTS
Global Point of Care Molecular Diagnostics Market is expected to register huge progress at a notable CAGR of 9.2% by 2031
Global Point of Care Molecular Diagnostics Market to surpass USD 7.6 billion by 2031 from USD 3.2 billion in 2021 at a CAGR of 9.2% in the coming years, i.e., 2021-2031. The Point of Care Molecular Diagnostics Market is being driven by factors such as the rising prevalence of infectious diseases & cancer, a growing focus on decentralized diagnostics, and increased R&D investment. Furthermore, growing awareness of the early diagnosis of infectious diseases and increased usage of point-of-care diagnostic tests are other drivers driving market expansion.
GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SEGMENTS
Assays & Kits segment is predicted to lead the market over the forecast period with maximum CAGR
By Product and Service, the Global Point of Care Molecular Diagnostics Market is divided into Assays & Kits, Instruments & Analyzers, and Software & Services. The sector of assays and kits held the greatest share of the market. The market expansion of this sector is driven by frequent purchases of these products due to their regular use. Today, a diverse range of kits and assays are available for monitoring and diagnosing a wide range of disorders.
RT-PCR segment is expected to witness a higher share of the market in the near future
By Technology, the Global Point of Care Molecular Diagnostics Market is divided into RT-PCR, INAAT, and Other Technologies. The RT-PCR sector had the most market share. The expanding usage of RT-PCR in proteomics, COVID-19 testing, genomics, as well as the availability of portable, easy-to-use instruments, are the primary drivers of this market segment's growth.
MARKET DYNAMICS
Drivers
Growing number of cancer patients and individuals affected with infectious diseases across the globe is majorly boosting the market
The shift from centralized to decentralized owing to its simplicity, convenience, and other benefits is propelling the market growth
Restraint
Insufficient reimbursements are hampering the market growth of Global Point of Care Molecular Diagnostics
.
GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
Key Players
Global Point of Care Molecular Diagnostics Market Segments:
PRODUCT OVERVIEW
Molecular diagnostic testing blends laboratory testing with molecular biology precision, revolutionizing how clinical and public health laboratories explore human, viral, and microbial genomes, genes, and the products they encode. Various conventional tests have been replaced by molecular diagnostic assays in many areas of laboratory medicine, including infectious diseases, oncology, clinical genetics, and clinical chemistry. Furthermore, advances in molecular diagnostic testing will continue to improve the precision and speed with which we can detect microbial infections or study a patient's genes, and it will become an increasingly important part of patient-tailored interventions and medicines.
MARKET HIGHLIGHTS
Global Point of Care Molecular Diagnostics Market is expected to register huge progress at a notable CAGR of 9.2% by 2031
Global Point of Care Molecular Diagnostics Market to surpass USD 7.6 billion by 2031 from USD 3.2 billion in 2021 at a CAGR of 9.2% in the coming years, i.e., 2021-2031. The Point of Care Molecular Diagnostics Market is being driven by factors such as the rising prevalence of infectious diseases & cancer, a growing focus on decentralized diagnostics, and increased R&D investment. Furthermore, growing awareness of the early diagnosis of infectious diseases and increased usage of point-of-care diagnostic tests are other drivers driving market expansion.
GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SEGMENTS
Assays & Kits segment is predicted to lead the market over the forecast period with maximum CAGR
By Product and Service, the Global Point of Care Molecular Diagnostics Market is divided into Assays & Kits, Instruments & Analyzers, and Software & Services. The sector of assays and kits held the greatest share of the market. The market expansion of this sector is driven by frequent purchases of these products due to their regular use. Today, a diverse range of kits and assays are available for monitoring and diagnosing a wide range of disorders.
RT-PCR segment is expected to witness a higher share of the market in the near future
By Technology, the Global Point of Care Molecular Diagnostics Market is divided into RT-PCR, INAAT, and Other Technologies. The RT-PCR sector had the most market share. The expanding usage of RT-PCR in proteomics, COVID-19 testing, genomics, as well as the availability of portable, easy-to-use instruments, are the primary drivers of this market segment's growth.
MARKET DYNAMICS
Drivers
Growing number of cancer patients and individuals affected with infectious diseases across the globe is majorly boosting the market
The shift from centralized to decentralized owing to its simplicity, convenience, and other benefits is propelling the market growth
Restraint
Insufficient reimbursements are hampering the market growth of Global Point of Care Molecular Diagnostics
.
GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
Key Players
- Abbott Laboratories
- Bayer AG
- BioMerieux SA
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Nova Biomedical
- OraSure Technologies, Inc.
- Qiagen Gmbh
- Sekisui Medical Co., Ltd.
- Zoetis Inc.
- Other Prominent Players
Global Point of Care Molecular Diagnostics Market Segments:
- By Product & Service
- Assays & Kits
- Instruments & Analyzers
- Software & Services
- By Technology
- RT-PCR
- INAAT
- Other Technologies
- By Application
- Respiratory Diseases
- Sexually Transmitted Diseases
- Hospital-acquired Infections
- Cancer
- Hepatitis
- Gastrointestinal Disorders
- Other Applications
- By End-User
- Physicians’ Offices
- Hospitals & ICUs
- Research Institutes
- Other End Users
- Global Point of Care Molecular Diagnostics Market Dynamics
- Global Point of Care Molecular Diagnostics Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
Executive Summary
2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3 RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4 AVERAGE PRICING ANALYSIS
5 MACRO-ECONOMIC INDICATORS
6 MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7 CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8 RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9 RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Latin America: (Rest of Latin America), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Europe: (Germany, UK, France, Italy, Rest of Europe), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Asia-Pacific: (China, India, Japan, Rest of Asia Pacific), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.5. Middle East and Africa: (North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Product & Service: Market Share (2020-2031F)
12.2.1. Assays & Kits, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Instruments & Analyzers, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.3. Software & Services, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Technology: Market Share (2020-2031F)
12.3.1. RT-PCR, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. INAAT, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Other Technologies, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By Application: Market Share (2020-2031F)
12.4.1. Respiratory Diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Sexually Transmitted Diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Hospital-acquired Infections, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Cancer, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.5. Hepatitis, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.6. Gastrointestinal Disorders, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.7. Other Applications, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5. By End User: Market Share (2020-2031F)
12.5.1. Physicians’ Offices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.2. Hospitals & ICUs, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.3. Research Institutes, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.4. Other End Users, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13 COMPANY PROFILE
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Bayer AG
13.3. BioMerieux SA
13.4. Bio-Rad Laboratories, Inc.
13.5. Danaher Corporation
13.6. F. Hoffmann-La Roche Ltd.
13.7. Nova Biomedical
13.8. OraSure Technologies, Inc.
13.9. Qiagen Gmbh
13.10. Sekisui Medical Co., Ltd.
13.11. Zoetis Inc.
13.12. Other Prominent Players
14 CONSULTANT RECOMMENDATION
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3 RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4 AVERAGE PRICING ANALYSIS
5 MACRO-ECONOMIC INDICATORS
6 MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7 CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8 RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9 RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Latin America: (Rest of Latin America), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Europe: (Germany, UK, France, Italy, Rest of Europe), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Asia-Pacific: (China, India, Japan, Rest of Asia Pacific), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.5. Middle East and Africa: (North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Product & Service: Market Share (2020-2031F)
12.2.1. Assays & Kits, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Instruments & Analyzers, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.3. Software & Services, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Technology: Market Share (2020-2031F)
12.3.1. RT-PCR, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. INAAT, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Other Technologies, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By Application: Market Share (2020-2031F)
12.4.1. Respiratory Diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Sexually Transmitted Diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Hospital-acquired Infections, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Cancer, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.5. Hepatitis, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.6. Gastrointestinal Disorders, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.7. Other Applications, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5. By End User: Market Share (2020-2031F)
12.5.1. Physicians’ Offices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.2. Hospitals & ICUs, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.3. Research Institutes, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.5.4. Other End Users, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13 COMPANY PROFILE
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Bayer AG
13.3. BioMerieux SA
13.4. Bio-Rad Laboratories, Inc.
13.5. Danaher Corporation
13.6. F. Hoffmann-La Roche Ltd.
13.7. Nova Biomedical
13.8. OraSure Technologies, Inc.
13.9. Qiagen Gmbh
13.10. Sekisui Medical Co., Ltd.
13.11. Zoetis Inc.
13.12. Other Prominent Players
14 CONSULTANT RECOMMENDATION
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
